Day: May 27, 2020

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference at 8:00 a.m. ET on Thursday, June 4, 2020. The presentation will be webcast live and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.About CalitheraCalithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells...

RAMSEY, N.J. and BOCA RATON, Fla., May 27, 2020 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 2:00 p.m. ET.A webcast of the event will be available on the Company’s website at https://ir.admabiologics.com/events-webcasts and will be archived for 90 days following the event.About ADMA Biologics, Inc. (ADMA)ADMA Biologics is an end-to-end commercial biopharmaceutical...

No. 8/2020Copenhagen, 27 May 2020The Annual General Meeting of Lauritz.com Group A/S took place today, Wednesday 27 May 2020.The General Meeting approved the following:The election of Jens Arnesen, attorney-at-law, as chairman of the meeting.The Annual Report 2019 as well as the Board of Directors proposal regarding the distribution of the profit for the year, including a dividend of DKK 0.00 per share.As proposed by the Board of Directors Bengt Olof Tony Sundström was re-elected as Chairman of the Board of Directors.As proposed by the Board of Directors, Bengt Olof Tony Sundström, Claus Due Pedersen, Mette Rode Sundstrøm and Preben Vinkler Lindgaard was re-elected as members of the Board of Directors.As proposed by the Board of Directors, the auditing firm Deloitte Statsautoriseret Revisionspartnerselskab, was elected as auditor.The...

EWING, N.J., May 27, 2020 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 10:00 a.m. Eastern Time.A live webcast of the presentation will be available under the “For Investors” section of the Antares website, www.antarespharma.com.About Antares PharmaAntares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances...

MISSISSAUGA, Ontario, May 27, 2020 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has begun a build-out of its second facility that is initially intended to support a tenfold increase of production capacity for its QAPs™ quality assessment products – which support the accuracy of clinical laboratory testing including, but not limited to, support for tests for the SARS-CoV-2 virus causing COVID-19 disease. Microbix’s current maximum QAPs production capacity is limited by the space allotted in its wholly-owned facility that is primarily dedicated to making its range of antigens for immunoassay/serological test production. That capacity will be exceeded if Microbix achieves its growth objectives for QAPs.The capacity expansion now underway...

REDWOOD CITY, Calif., May 27, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate in two virtual investment conferences:17th Annual Craig-Hallum Institutional Investor Conference being held in a one-on-one meeting format on Wednesday, May 27.Jefferies Virtual Healthcare Conference with presentation on Tuesday, June 2, at 2:00 p.m. Eastern time (11:00 a.m. Pacific time).   A live webcast and replay of the Jefferies Conference presentation will be available on the Investors section of the company’s website, http://ir.codexis.com/.About Codexis, Inc.Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture...

MAROUSSI, ATHENS, Greece, May 27, 2020 (GLOBE NEWSWIRE) — Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today its results for the three-month period ended March 31, 2020.First Quarter 2020 Financial Highlights:Total net revenues of $15.4 million. Net income of $2.0 million; net income attributable to common shareholders (after a $0.2 million of dividend on Series B Preferred Shares) of $1.8 million or $0.32 per share basic and diluted. Adjusted net income attributable to common shareholders¹ for the period was $1.0 million or $0.17 per share basic and diluted.Adjusted EBITDA¹ was $4.1 million.An average of 19.0 vessels were owned and operated during the first quarter of 2020 earning an average...

VANCOUVER, British Columbia, May 27, 2020 (GLOBE NEWSWIRE) — Coro Mining Corp. (“Coro” or the “Company”) is pleased to announce it has changed its name to Marimaca Copper Corp. (“Marimaca Copper”) to align with its flagship development project in Chile. The Company has also undertaken a 25:1 share consolidation as part of a capital reorganisation.The Company’s new website address is www.marimaca.com where its latest investor presentation can be found. An interview with the recently appointed Executive Chairman, Michael Haworth, can be found at https://www.b-tv.com/coro-mining-changes-name-to-marimaca-copper-corp-news-alert-30sec.The Company’s new ticker will be MARI and trading under the new name on the TSX will commence today, the 27th of May 2020.Michael Haworth, Executive Chairman commented:“The Marimaca Copper Project is one...

EDINBURGH, United Kingdom, May 27, 2020 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference.Event: Jefferies Virtual Healthcare ConferencePresentation Date: Wednesday, June 3, 2020Presentation Time: 10:00 AM ETThe presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company’s website at www.nucana.com.About NuCana plcNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more...

– The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist –– Safety Data Reinforce Excellent Tolerability Profile of Zygel –– Zynerba to host conference call and webcast today, May 27, 2020 at 8:30 am ET –DEVON, Pa., May 27, 2020 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced positive top line results from the exploratory, open label Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder) trial.The trial was designed to assess...